Antonio Renta Munoz, MD
Cardiology · Hato Rey, PRNPI 1891791000
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $22,593 of the $36,421 with a category attached, or 62.0%. 13 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 45.5% of the total. Reporting peaked in 2019 at $20,883 and has fallen 98.1% since, to $402 in 2025.
Across 162 payments — averaging $224.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$17K
- Pfizer Pharmaceuticals LLC$9K
- Pfizer$5K
- Merck$3K
- Johnson & Johnson$826
- Amgen$726
- plus $2K from 7 others
What the payments were for
- Consulting fees$7,78321%
- Speaking & faculty fees$22,59362%
- Travel & lodging$1,2483%
- Food & beverage$4,77813%
- Education$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 36 | $16,574 |
| Pfizer Pharmaceuticals LLC | 7 | $8,773 |
| Pfizer | 5 | $5,185 |
| Merck | 6 | $2,526 |
| Johnson & Johnson | 21 | $826 |
| Amgen | 16 | $726 |
| Boehringer Ingelheim | 32 | $656 |
| PBG Puerto Rico LLC | 23 | $469 |
| Boston Scientific | 4 | $352 |
| AstraZeneca | 7 | $190 |
| GSK | 3 | $69 |
| Janssen Scientific Affairs, LLC | 1 | $50 |
| Novartis | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few cardiology providers in Puerto Ricoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 285 | $231,708 |
| JanumetSitagliptin Phos/Metformin Hcl | 54 | $43,095 |
| BrilintaTicagrelor | 49 | $34,195 |
| FarxigaDapagliflozin Propanediol | 41 | $33,637 |
| XareltoRivaroxaban | 43 | $33,376 |
| SynthroidLevothyroxine Sodium | 377 | $28,810 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 29 | $23,812 |
| JardianceEmpagliflozin | 15 | $20,325 |
| Repatha SureclickEvolocumab | 28 | $16,769 |
| JanuviaSitagliptin Phosphate | 14 | $14,841 |
| Candesartan Cilexetil | 150 | $13,683 |
| Repatha SyringeEvolocumab | 11 | $11,067 |
| TradjentaLinagliptin | 12 | $10,321 |
| Metoprolol Succinate | 651 | $10,199 |
| Jentadueto XrLinagliptin/Metformin Hcl | 11 | $7,836 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $5,185 | $231,708285 claims |
| MerckJanumet, Janumet Xr, Januvia | $2,526 | $81,74897 claims |
| AstraZenecaBrilinta, Farxiga | $190 | $67,83290 claims |
| Boehringer IngelheimJardiance, Tradjenta, Jentadueto Xr, Jentadueto, Pradaxa | $656 | $46,72561 claims |
| Johnson & JohnsonXarelto | $826 | $33,37643 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cardiology providers in Puerto Ricoon file to place this against a meaningful peer group, so we don't.
Other cardiology in Hato Rey
- Ralph Conaway LanuzaHato Rey$2K
- Juan Rodriguez AcostaMayaguez$15K
- Norma Devarie DiazSan Juan$8K
- Rafael Ufret-PerezCaguas$7K
- Jose Martinez ToroSan Juan$5K
- Felix Rios GonzalezTrujillo Alto$4K
- Alexis Rivera-DavilaFajardo$4K
- Manuel ArecesSanjuan$4K
- Hiram Cardona-MartinezMayaguez$3K
- Roberto Munoz-MarinSanturce$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.